SC
segMedix develops an AI-powered platform for prostate cancer diagnosis that utilizes deep learning models for precise MRI image analysis, enabling accurate prostate segmentation and advanced lesion detection. This technology reduces the time radiologists spend on scans while improving diagnostic efficiency and accuracy, achieving a segmentation accuracy of 98.7%.
Updated 4 months ago
Funding
$60K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- segMedix develops an AI-powered platform for prostate cancer diagnosis that utilizes deep learning models for precise MRI image analysis, enabling accurate prostate segmentation and advanced lesion detection. This technology reduces the time radiologists spend on scans while improving diagnostic efficiency and accuracy, achieving a segmentation accuracy of 98.7%.